Filing Flows › 13F managers › Merck & Co.
Merck & Co.: 13F portfolio Q2 2026 and what copying it returned
Merck & Co.'s 13F for the quarter ended 2026-06-30 (filed Aug 7, 2026): 13 common-share positions, $526M reported. Copying each 13F the day after it was filed returned +477.0% from May 16, 2025 to Nov 6, 2026, against +24.5% for SPY.
Copying the 13F
Each 13F bought at the close of the first trading day after it was filed and held, drifting, until the next one; value-weighted over the common-share positions with a price (91.4% of the portfolio on average); 6 filings since May 14, 2025. Price returns for the clone and SPY alike (no dividends, no costs). A 13F lists only US long positions at quarter end, reported up to 45 days later.
Largest holdings (2026-06-30)
| Ticker | Company | Weight | Value | Change in the quarter |
|---|---|---|---|---|
| PSNL | Personalis | 35.8% | $188M | unchanged |
| MRNA | Moderna | 30.7% | $162M | unchanged |
| KYMR | Kymera Therapeutics | 16.8% | $88.5M | unchanged |
| AKTS | Aktis Oncology | 5.8% | $30.7M | unchanged |
| EIKN | Eikon Therapeutics | 4.1% | $21.7M | unchanged |
| TRDA | Entrada Therapeutics | 2.4% | $12.8M | new |
| STRO | Sutro Biopharma | 1.7% | $9.0M | new |
| ALEC | Alector | 1.4% | $7.1M | unchanged |
| EVAX | Evaxion A/S | 0.7% | $3.8M | new |
| VRDN | Viridian Therapeutics | 0.3% | $1.7M | unchanged |
| XLO | Xilio Therapeutics | 0.2% | $1.0M | unchanged |
| HURA | TuHURA Biosciences | 0.0% | $46K | unchanged |
| NEUP | Neuphoria Therapeutics | 0.0% | $44K | unchanged |
Biggest adds
- TRDA new
- STRO new
- EVAX new
Biggest cuts
- None reported.
Track record
Of 7 position changes scored in 7 separate decisions, 57.1% were on the right side of SPY over the next three months (Disclosures → Smart money).
Open in Disclosures → every quarter, the clone month by month, the smart-money record
Source: SEC Form 13F-HR, filer CIK 310158. Not investment advice.